Patents by Inventor Klaus Giese
Klaus Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11578328Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 7, 2020Date of Patent: February 14, 2023Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20210261980Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
-
Publication number: 20210062198Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 7, 2020Publication date: March 4, 2021Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 10774332Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 3, 2019Date of Patent: September 15, 2020Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20190390201Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 3, 2019Publication date: December 26, 2019Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 10329568Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: September 5, 2018Date of Patent: June 25, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 10323246Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 15, 2017Date of Patent: June 18, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 10266829Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: June 20, 2018Date of Patent: April 23, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20190024089Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: September 5, 2018Publication date: January 24, 2019Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20180291381Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: June 20, 2018Publication date: October 11, 2018Applicant: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20180223286Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 15, 2017Publication date: August 9, 2018Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 9790505Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 12, 2017Date of Patent: October 17, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9790501Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 8, 2017Date of Patent: October 17, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9783802Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 12, 2017Date of Patent: October 10, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 9758784Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 8, 2017Date of Patent: September 12, 2017Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20170247691Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247698Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 8, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247697Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 8, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20170247707Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 12, 2017Publication date: August 31, 2017Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 9695423Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: December 22, 2015Date of Patent: July 4, 2017Assignee: SILENCE THERAPEUTICS GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese